摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-propylpiperidine-4-carboxamide

中文名称
——
中文别名
——
英文名称
1-propylpiperidine-4-carboxamide
英文别名
4-carboxamide-1-propylpiperidine
1-propylpiperidine-4-carboxamide化学式
CAS
——
化学式
C9H18N2O
mdl
MFCD18102254
分子量
170.255
InChiKey
DNBUALMNLLJERK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    12
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.888
  • 拓扑面积:
    46.3
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-propylpiperidine-4-carboxamidesodium hydroxide 作用下, 以 四氢呋喃 、 lithium aluminium tetrahydride 、 为溶剂, 生成 C-(1-丙基-哌啶-4-基)-甲胺
    参考文献:
    名称:
    Substituted 2- (S) -hydroxy-3- (piperidin-4-yl-methylamino) -propyl ethers and substituted 2-aryl-2- (R) - hydroxy-1- (piperidin-4-yl-methyl) -ethylamine beta-3 adrenergic receptor agonists
    摘要:
    这项发明提供了具有结构式1的化合物,其中A、B、Z、R和R1如前文所定义,或其药学上可接受的盐,用于治疗或抑制与胰岛素抵抗或高血糖相关的代谢紊乱(通常与肥胖或葡萄糖不耐受有关)、动脉粥样硬化、胃肠道疾病、神经炎症、青光眼、眼压增高和频繁排尿;特别适用于治疗或抑制2型糖尿病。
    公开号:
    US20020037907A1
  • 作为产物:
    描述:
    哌啶-4-甲酰胺1-碘代丙烷potassium carbonate 作用下, 以 乙醇 为溶剂, 反应 15.0h, 以92%的产率得到1-propylpiperidine-4-carboxamide
    参考文献:
    名称:
    Synthesis and evaluation of novel serotonin 4 receptor radiotracers for single photon emission computed tomography
    摘要:
    Despite its implication in several physiological and pathological processes the serotonin subtype-4 receptor (5-HT4R) has seen limited effort for the development of radiolabeling agent especially concerning single photon emission computed tomography (SPECT). Bearing an ester function, the available ligands are rapidly susceptible to hydrolysis which limits their use in vivo. In this study the synthesis of iodinated benzamide and ketone analogs were described. Their affinity for the 5-HT4R and their lipophilicity were evaluated and the most promising derivatives were evaluated ex vivo for their binding to the receptor and for their ability to displace the reference ligand [I-125]-SB207710. (C) 2016 Elsevier Masson SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2016.03.059
点击查看最新优质反应信息

文献信息

  • New Piperazine Compound and Use Thereof as a HCV Polymerase Inhibitor
    申请人:Abe Hiroyuki
    公开号:US20080081818A1
    公开(公告)日:2008-04-03
    The present invention relates to a compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof and an anti-HCV agent and an HCV polymerase inhibitor containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.
    本发明涉及一种由以下式[I]表示的化合物,其中每个符号如规范中定义,或其药学上可接受的盐,或其溶剂化合物,以及含有该化合物的抗HCV剂和HCV聚合酶抑制剂。本发明的化合物基于HCV聚合酶抑制活性显示出抗HCV活性,并且可用作预防或治疗丙型肝炎的药剂。
  • [EN] MICROSOMAL PROSTAGLANDIN E SYNTHASE-1 (MPGES1) INHIBITORS<br/>[FR] INHIBITEURS DE PROSTAGLANDINE E SYNTHASE-1 (MPGES1) MICROSOMALE
    申请人:NOVASAID AB
    公开号:WO2011023812A1
    公开(公告)日:2011-03-03
    A compound of formula (I): as well as pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising the compound. The compound is useful for the treatment of disorder selected from inflammatory diseases, nociceptive pain, auto-immune disease, breathing disorders, fever, cancer, inflammation related anorexia, Alzheimer's disease and cardiovascular diseases.
    公式(I)的化合物,以及其药用盐,以及包括该化合物的药物组合物。该化合物用于治疗选择自炎性疾病、伤害性疼痛、自身免疫疾病、呼吸系统疾病、发热、癌症、与炎症相关的厌食症、阿尔茨海默病和心血管疾病的紊乱。
  • Substituted 2- (S) -hydroxy-3- (piperidin-4-yl-methylamino) -propyl ethers and substituted 2-aryl-2- (R) - hydroxy-1- (piperidin-4-yl-methyl) -ethylamine beta-3 adrenergic receptor agonists
    申请人:American Home Products Corporation
    公开号:US20020037907A1
    公开(公告)日:2002-03-28
    This invention provides compounds of Formula I having the structure 1 wherein A, B, Z, R and R 1 are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.
    这项发明提供了具有结构式1的化合物,其中A、B、Z、R和R1如前文所定义,或其药学上可接受的盐,用于治疗或抑制与胰岛素抵抗或高血糖相关的代谢紊乱(通常与肥胖或葡萄糖不耐受有关)、动脉粥样硬化、胃肠道疾病、神经炎症、青光眼、眼压增高和频繁排尿;特别适用于治疗或抑制2型糖尿病。
  • DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS
    申请人:Molteni Valentina
    公开号:US20090264649A1
    公开(公告)日:2009-10-22
    Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.
    本文描述了一些包括二芳基胺结构特征的化合物。还描述了制备这些化合物的方法,利用这些化合物调节c-kit受体活性的方法,以及包含这些化合物的药物组合物和药物。本文还描述了使用这些化合物、药物组合物和药物来治疗和/或预防和/或抑制和/或改善与c-kit受体活性相关的疾病或症状的方法。
  • Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine &bgr;-3 adrenergic receptor agonists
    申请人:Wyeth
    公开号:US06506901B2
    公开(公告)日:2003-01-14
    This invention provides compounds of Formula I having the structure wherein A, B, Z, R and R1 are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.
    本发明提供具有式I的化合物,其结构中A、B、Z、R和R1如前所定义,或其药学上可接受的盐,这些化合物在治疗或抑制与胰岛素抵抗或高血糖相关的代谢紊乱(通常与肥胖或葡萄糖耐受性不良有关)、动脉粥样硬化、胃肠道疾病、神经遗传性炎症、青光眼、眼压增高和频繁排尿方面非常有用;并且在治疗或抑制II型糖尿病方面特别有用。
查看更多